9M 2023 Financial Performance

9M 2023: APPENDIX Lu AG13909 - First neurohormonal program started clinical development Hypothalamic-pituitary-adrenal (HPA) axis Hypothalamus CRH Corticotroph + Pituitary gland Negative Feedback ACTH + Aldosterone Androgens Adrenal Glands Cortisol 27 ACTH: adrenocorticotropic hormone. HPA axis: hypothalamic-pituitary-adrenal axis Medical condition • Neurohormonal dysfunctions related to HPA axis Molecule Anti-ACTH humanized IgG1 antibody First in class mAb with potential to offer a safe and efficacious treatment alternative to patients suffering from conditions with increased ACTH Clinical development phase Clinical development program was initiated December 2022

View entire presentation